TrialPloS one2011

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Ranjan Chrisanthar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.